Zacks: Brokerages Expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will Post Earnings of -$0.53 Per Share

Brokerages expect Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Rating) to report ($0.53) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for Mersana Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.48). Mersana Therapeutics posted earnings of ($0.59) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 10.2%. The business is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.51) to ($1.98). For the next fiscal year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.62) to ($1.75). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSNGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.28). Mersana Therapeutics had a negative return on equity of 119.10% and a negative net margin of 8,826.73%. During the same quarter last year, the firm posted ($0.50) earnings per share.

MRSN has been the subject of several research reports. SVB Leerink reduced their price objective on shares of Mersana Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, February 18th. HC Wainwright reduced their price objective on shares of Mersana Therapeutics from $24.00 to $19.00 in a research report on Monday, May 9th. Robert W. Baird reduced their price objective on shares of Mersana Therapeutics from $23.00 to $18.00 in a research report on Tuesday, May 10th. Finally, Zacks Investment Research cut shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $17.80.

Shares of MRSN stock traded down $0.11 during trading hours on Friday, reaching $3.15. The stock had a trading volume of 53,977 shares, compared to its average volume of 1,724,128. The firm has a market capitalization of $305.52 million, a PE ratio of -1.31 and a beta of 2.37. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.28 and a quick ratio of 4.28. The firm has a 50-day simple moving average of $3.87 and a 200-day simple moving average of $5.10. Mersana Therapeutics has a twelve month low of $2.68 and a twelve month high of $15.34.

In other Mersana Therapeutics news, Director Andrew A. F. Hack acquired 135,292 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The shares were purchased at an average price of $3.10 per share, with a total value of $419,405.20. Following the completion of the transaction, the director now owns 7,872,692 shares in the company, valued at $24,405,345.20. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Andrew A. F. Hack acquired 598,086 shares of the business’s stock in a transaction that occurred on Tuesday, April 12th. The shares were acquired at an average cost of $4.18 per share, for a total transaction of $2,499,999.48. Following the transaction, the director now owns 7,120,116 shares of the company’s stock, valued at approximately $29,762,084.88. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,060,245 shares of company stock valued at $4,025,409. 5.30% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in MRSN. Marshall Wace LLP bought a new position in shares of Mersana Therapeutics in the first quarter valued at approximately $141,000. Morgan Stanley grew its stake in shares of Mersana Therapeutics by 853.2% in the second quarter. Morgan Stanley now owns 126,177 shares of the company’s stock worth $1,713,000 after acquiring an additional 112,940 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Mersana Therapeutics by 65.4% in the second quarter. Bank of America Corp DE now owns 55,232 shares of the company’s stock worth $750,000 after acquiring an additional 21,841 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Mersana Therapeutics in the third quarter worth $346,000. Finally, Swiss National Bank grew its stake in shares of Mersana Therapeutics by 1.8% in the third quarter. Swiss National Bank now owns 122,996 shares of the company’s stock worth $1,160,000 after acquiring an additional 2,200 shares during the last quarter. 92.74% of the stock is currently owned by institutional investors.

About Mersana Therapeutics (Get Rating)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Featured Articles

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.